Florian Dieckmann new VP Global Communications at Grünenthal
AACHEN, Germany, Jan. 12, 2021 /PRNewswire/ Florian Dieckmann joined Grünenthal as the new Vice President and Head Global Communications on 1 January 2021. He succeeds Štepán Krácala, who transformed the research-driven pharmaceutical company s Communications department from 2018 until the end of last year. Florian Dieckmann now leads Grünenthal s communications activities across almost 30 markets worldwide, and manages the team at the company s headquarters in Aachen. He reports directly to CEO Gabriel Baertschi.
As a fully integrated pharmaceutical company, Grünenthal aims to further strengthen its research and innovation capacities in the field of pain therapy, and to tap into additional commercial growth opportunities in its core markets - particularly in Europe, the USA and Latin America. The company has completed several acquisitions and entered into a wide range of strategic partnerships in recent years. T
Share:
AACHEN, Germany, Dec. 16, 2020 /PRNewswire/ Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of chronic peripheral neuropathic pain.
The Phase I trial will include 76 healthy participants. The trial aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound following single and multiple-ascending doses. The results of the study are expected to be available in 2021. Pain remains a high unmet medical need that we strive to address with innovative medicines. Progressing our peripheral NOP agonist into clinical development is a major success in our efforts to build an industry-leading pipeline of investigational medicines, says Jan Adams, M.D., Chief Scientific Officer, Grünenthal. By driv